MedTrace Logo

Change of NLRP3 Inflammasome Expression Level, Symptoms, and Functional Status in HFpEF Patients Treated With ARNI

NCT04269057 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2020-02-17

No results posted yet for this study

Summary

Underlying inflammation has been increasingly recognized in heart failure with a preserved ejection fraction(HFpEF). But there is no study reported the relationship between NLRP3 inflammasome and HFpEF. In this study, investigators propose a scientific hypothesis that the expression of NLRP3 inflammasome is elevated in patients with HFpEF, and the level of TNFα, IL-1β and NLRP3 inflammasome is lower in patients treated with sacubitril/valsartan.

Conditions

Sponsors & Collaborators

  • Chongqing Medical University

    lead OTHER

Principal Investigators

  • Dongying Zhang, doctor · First Affiliated Hospital of Chongqing Medical University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2020-10-01
Completion
2020-10-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04269057 on ClinicalTrials.gov